All In Biotech

Drug Trial Radar · NCT07896590

Orelabrutinib Plus ICP 248 vs Orelabrutinib for Relapsed/Refractory Marginal Zone Lymphoma

A Randomized, Multicenter, Open Label Phase 3 Study to Evaluate Orelabrutinib Combined With ICP 248 Versus Orelabrutinib Monotherapy for Relapsed/Refractory Marginal Zone Lymphoma

Last checked: Nov 19, 2026Latest source record: Oct 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 292 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

292

Planned (sponsor's estimate)

Start

Oct 2026

Primary completion

Oct 2028

Study completion Jan 2032

Sponsor

Sponsor type
Industry
First posted
Oct 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy of olubrutinib combined with ICP-248 compared with the olubrutinib in the treatment of r/r MZL

Conditions

  • Relapsed/Refractory Marginal Zone Lymphoma (MZL)

Interventions

  • OrelabrutinibDrug

    Participants receive orelabrutinib 150 mg oral once daily continuous dosing; each cycle is 28 days.

  • ICP-248Drug

    Eligible patients will receive ICP-248 orally as per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Complete Response Rate (CRR) assessed by Independent Review Committee (IRC)Time frame: Approximately 3 years.
  2. Progression Free Survival (PFS) assessed by Independent Review Committee (IRC)Time frame: Approximately 5 years.

Locations

46 sites in 1 country. Site status is shown where the registry gives one.

  • Shandong Cancer Hospital and Institute

    Jinan, China

  • Tianjin First Central Hospital

    Tianjin, China

  • Bozhou People's Hospital

    Bozhou, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • The First Affiliated Hospital of Anhui Medical University

    Hefei, Anhui, China

  • Anhui Provincial Cancer Hospital

    Hefei, Anhui, China

  • Peking University Cancer Hospital

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    Beijing, Beijing Municipality, China

  • Xinqiao Hospital Army Medical University

    Chongqing, Chongqing Municipality, China

  • Southwest Hospital, Army Medical University

    Chongqing, Chongqing Municipality, China

  • The First Affiliated Hospital of Fujian Medical University

    Fuzhou, Fujian, China

  • Fujian Cancer Hospital

    Fuzhou, Fujian, China

  • The First Affiliated Hospital of Xiamen University

    Xiamen, Fujian, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Sun Yat-sen University Cancer Center

    Guangzhou, Guangdong, China

  • Liuzhou People's Hospital

    Liuzhou, Guangxi, China

  • The Second Affiliated Hospital of Hainan Medical University

    Haikou, Hainan, China

  • The Fourth Hospital of Hebei Medical University

    Shijiazhuang, Hebei, China

  • Harbin Medical University cancer hospital

    Harbin, Heilongjiang, China

  • The First Affiliated Hospital of Henan University of Science and Technology

    Luoyang, Henan, China

  • The First Affiliated Hospital of Zhengzhou University

    Zhengzhou, Henan, China

  • Henan Cancer Hospital (The Affiliated Cancer Hospital of Zhengzhou University)

    Zhengzhou, Henan, China

  • Henan Provincial People's Hospital

    Zhengzhou, Henan, China

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • The Second Xiangya Hospital, Central South University

    Changsha, Hunan, China

  • Hunan Cancer Hospital

    Changsha, Hunan, China

  • Nanjing Drum Tower Hospital Affiliated to Medical School of Nanjing University

    Nanjing, Jiangsu, China

  • Jiangsu Provincial People's Hospital

    Nanjing, Jiangsu, China

  • The First Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, China

  • The First Hospital of China Medical University

    Shenyang, Liaoning, China

  • QiLu Hospital of Shandong University

    Jinan, Shandong, China

  • Shanghai Changzheng Hospital

    Shanghai, Shanghai Municipality, China

  • Fudan University Shanghai Cancer Center

    Shanghai, Shanghai Municipality, China

  • Shanxi Cancer Hospital

    Taiyuan, Shanxi, China

  • The first Affiliated Hospital Of Xi'an Jiaotong University

    Xi’an, Shanxi, China

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)

    Xi’an, Shanxi, China

  • Xijing Hospital, Air Force Medical University

    Xian, Shanxi, China

  • Sichuan Cancer Hospital

    Chengdu, Sichuan, China

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Showing 40 of 46 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.